Abstract: Vascular endothelial growth factor (VEGF)  plays an important role in the development of retinopathy of prematurity (ROP). Inhibition of VEGF expression with antiVEGF drugs in the neovascular phase of ROP might prevent destructive neovascularization in ROP. Clinical studies of application of bevacizumab (Avastin) in treatment of ROP in different ways which include intravitreal injection, intravitreal injection combined with retinal photocoagulation or vitrectomy were reviewed in this article. Safety of intravitreal injection of bevacizumab for treatment of ROP was also reviewed.  (Int Rev Ophthalmol, 2012, 36: 133137)